1. Home
  2. AQB vs ACXP Comparison

AQB vs ACXP Comparison

Compare AQB & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AquaBounty Technologies Inc.

AQB

AquaBounty Technologies Inc.

N/A

Current Price

$1.29

Market Cap

5.9M

Sector

N/A

ML Signal

N/A

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

SELL

Current Price

$1.02

Market Cap

6.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AQB
ACXP
Founded
1991
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
6.2M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
AQB
ACXP
Price
$1.29
$1.02
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
60.4K
★ 66.8K
Earning Date
11-17-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 87.66
N/A
EPS
★ N/A
N/A
Revenue
★ $2,472,659.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$400.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.82
$1.04
52 Week High
$6.25
$7.54

Technical Indicators

Market Signals
Indicator
AQB
ACXP
Relative Strength Index (RSI) 58.99 38.68
Support Level $1.01 $1.07
Resistance Level $1.24 $1.75
Average True Range (ATR) 0.09 0.06
MACD 0.02 0.00
Stochastic Oscillator 80.00 35.35

Price Performance

Historical Comparison
AQB
ACXP

About AQB AquaBounty Technologies Inc.

AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: